Clinical Trials Logo

Clinical Trial Summary

The goal of this randomized clinical trial is to assess if adjunctive bosentan therapy, in comparison to placebo, can reduce the rate of epicardial vasospasm at follow-up spasm provocation CFT (fuCFT) in patients with previously proven epicardial vasospasm on acetylcholine reactivity testing (at index CFT) and ongoing angina(-like) complaints. Participants will - Use either endothelin receptor antagonist or placebo for 10 weeks - Undergo follow-up acetylcholine spasm provocation test after 10 weeks - Answer online questionnaires on angina and quality of life


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06432452
Study type Interventional
Source Radboud University Medical Center
Contact Peter Damman
Phone 0243616785
Email peter.damman@radboudumc.nl
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date August 1, 2024
Completion date April 1, 2026